Selected article for: "hoc test and post hoc test"

Author: Prerana Shrestha; Pinar Ayata; Pedro Herrero-Vidal; Francesco Longo; Alexandra Gastone; Joseph E. Ledoux; Nathaniel Heintz; Eric Klann
Title: Chemogenetic evidence that rapid neuronal de novo protein synthesis is required for consolidation of long-term memory
  • Document date: 2019_7_17
  • ID: llzdwza1_29
    Snippet: Standard 5-min test duration was applied and the maze was wiped with 30% ethanol in between trials. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/704965 doi: bioRxiv preprint the linear range and then normalized by total protein and quantified via densitometry using ImageJ software. labeled with 10 μCi TRAN 35 compared to ASV-treated wild-type slices and VEH-treated Nes.iP.....
    Document: Standard 5-min test duration was applied and the maze was wiped with 30% ethanol in between trials. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/704965 doi: bioRxiv preprint the linear range and then normalized by total protein and quantified via densitometry using ImageJ software. labeled with 10 μCi TRAN 35 compared to ASV-treated wild-type slices and VEH-treated Nes.iPKR slices (****p<0.0001). ). n=3 biological peak expression of 36 kDa iPKR at 0.5h, which was undetectable at 6h (****p<0.0001). Endogenous PKR (68 826 kDa) remained unchanged after ASV treatment. Peak expression of p-eIF2α, normalized for t-eIF2α, was 827 achieved at 0.5h after ASV infusion followed by a steady decline from 3h onwards (*p<0.05). ATF4 and 828 GADD34 proteins whose transcripts harbor a uORF, were increased by ASV by 1h and and decline to baseline Nes.iPKR amygdala slices treated with ASV (5 nM) applied before the tetanus and perfused for 90 min 835 following tetanus (****p<0.0001, n = 12-15 slices/ group). One-way ANOVA with Bonferroni's post-hoc test. g)

    Search related documents:
    Co phrase search for related documents
    • 1h ASV increase and ASV treatment: 1
    • 1h ASV increase and peak expression: 1
    • 1h ASV increase and wild type: 1
    • ASV increase and peak expression: 1
    • ASV increase and wild type: 1
    • ASV treatment and peak expression: 1
    • ASV treatment and wild type: 1, 2
    • baseline decline and steady decline: 1